News

A new Mayo Clinic study has found that patients with microvascular endothelial dysfunction were more than twice as likely to be diagnosed with solid-tumor cancer than their counterparts without dysfunction.

Of the predominating risk factors or comorbidities that occur with HF, hypertension appears to be the most prevalent.

After decades of development, researchers are nearing clinical trials for immune response-shifting vaccines. Will they be feasible for patients, and accepted by clinicians?

A new study from Icahn School of Medicine at Mount Sinai found increases in exposure to fine particulate matter before birth were associated with heart rate variability during infancy.

A new study from researchers at Penn Medicine and CHOP found bariatric surgery is not only effective, but safe for morbidly obese adolescents.

How can clinicians and policy makers collaborate to improve the standing of mental health in the US?

A discussion with a director from the American Public Health Association on what drives the increasing burden of mental illness in the US.

The IUD has been shown to provide 99% efficacy in pregnancy prevention in a 1700-patient trial.

A new assessment shows patients younger and older than 40 years both benefit in exacerbation rate and pre-bronchodilator FEV1.

The FDA approves Botox injections to treat pediatric patients with both upper and lower limb spasticity, unless it was caused by cerebral palsy.

A new study presented at CHEST 2019 shows pulmonologists and ILD specialists will either reduce or temporarily interrupt antifibrotic care, depending on the form of adverse events a patient is experiencing.

A study comparing the LAMA/LABA to monotherapy found patients without prior ICS treatment benefitted significantly, regardless of disease severity or symptoms.

A comparative cohort found inpatient and outpatient costs, both for respiratory and all-cause conditions, were less per month for patients on the antifibrotic.

New findings from the phase 3 trial show budesonide/ glycopyrrolate/ formoterol fumarate significantly reduces exacerbations among patients with no exacerbation history, compared to dual therapies.

A Cleveland Clinic study showed about 13% of its transfusions were in deference to current guidelines. That said, there's plenty of gray area for cause of care.

A new study finds the months of January-March are most burdened with COPD exacerbation-based hospitalizations, mortality, and hospital costs.

The rapid-acting insulin will now be used in infusion pumps to treat adults with Type 1 or Type 2 diabetes.

The FDA is allowing Rocket Pharmaceuticals to conduct a global phase I study testing a new treatment approach for Pyruvate Kinase Deficiency.

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.

Asthma burden among women can vary based on their age. Are there varying methods of care?

Fewer than 2% of all patients hospitalized with pneumonia in 2014 received the vaccination.

The chronic respiratory disease is often under-diagnosed in female patients.

The newly approved drug is a combination of 3 drugs that target the most common cystic fibrosis mutation.

The fixed-dose therapy was shown to reduce exacerbations, regardless of patient history, among those with increased cardiovascular risk.

AstraZeneca announced approval of the SGLT2 inhibitor for the reduction of hospitalization for heart failure in type 2 diabetes patients in a release on Monday.

Ustekinumab (Stelara) has received approval from the US Food and Drug Administration for the treatment of moderate to severely active ulcerative colitis in adults.

The approved label update now indicates the therapy delays disease progression when used in combination with an approved oral background PAH therapy.

A new assessment from CHRONICLE study data show patient-reported assessment on disease control may be more accurate.